Can I Take Resveratrol with AndroGel?

What Is AndroGel and Who Uses It?

AndroGel is a topical testosterone replacement therapy approved by the FDA for male hypogonadism, defined clinically as serum total testosterone below 300 ng/dL on two morning draws. The FDA-approved prescribing information for AndroGel 1.62% specifies starting doses of 40.5 mg (two pump actuations) applied to the shoulders or upper arms once daily, with titration up to 81 mg based on morning testosterone levels drawn 14 days after initiation or dose change. [1]

Who Is Prescribed AndroGel

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy in men with "unequivocally low serum testosterone concentrations and symptoms or signs of androgen deficiency," and it explicitly advises against treating men with total testosterone above 350 ng/dL. [2] In practice, the prescribing population includes men with primary hypogonadism, hypothalamic-pituitary disease, and age-related androgen decline documented by two separate lab draws before 10 a.m.

How Testosterone Gel Is Absorbed

Transdermal testosterone bypasses first-pass hepatic metabolism. Roughly 10% of the applied dose reaches systemic circulation, producing a gradual concentration rise over 2 to 8 hours and a relatively flat pharmacokinetic profile across the day compared with injections. Because absorption is dermal rather than hepatic, the CYP3A4 pathway becomes most relevant at the point of systemic clearance, not during absorption. [1]

What Is Resveratrol and Why Do Men on TRT Take It?

Resveratrol is a polyphenolic stilbene found in red grape skin, Japanese knotweed (Polygonum cuspidatum), and peanuts. Supplement products typically deliver 100 to 1,000 mg of trans-resveratrol per capsule, and the compound is widely marketed for cardiovascular protection, longevity signaling through SIRT1 activation, and anti-inflammatory effects.

Men on testosterone replacement often add resveratrol because of published data suggesting cardiovascular benefit, a concern that is directly relevant given that AndroGel labeling carries a warning about potential cardiovascular risk. [1] A 2018 randomized controlled trial in 75 men with metabolic syndrome found that resveratrol 1,000 mg/day for 3 months improved flow-mediated dilation and reduced fasting glucose, though it did not reach statistical significance for testosterone levels in that cohort. [3]

The SIRT1 and Longevity Angle

SIRT1, a NAD-dependent deacetylase, is one of resveratrol's proposed targets. Animal data from Baur et al. (2006) showed that high-dose resveratrol extended lifespan in obese mice fed a high-calorie diet, largely by mimicking caloric restriction pathways. [4] Human translation has proven inconsistent: a 2014 JAMA Internal Medicine study (N=783 older Italians) found no association between urinary resveratrol metabolites and all-cause mortality, cardiovascular events, or cancer incidence over 9 years. [5]

The CYP3A4 Interaction: Pharmacokinetics

This is the most direct pharmacokinetic concern. Testosterone is primarily metabolized by hepatic CYP3A4. Resveratrol inhibits CYP3A4 in a dose-dependent manner, as demonstrated in in-vitro microsomal studies and in a 2010 clinical pharmacology trial that found resveratrol 1,000 mg/day produced a modest but measurable reduction in midazolam (a CYP3A4 probe) clearance. [6]

What CYP3A4 Inhibition Means for Testosterone Levels

When CYP3A4 activity falls, testosterone clearance slows. The practical result is a modest rise in circulating testosterone and, by downstream aromatization, a parallel rise in estradiol. The magnitude depends on the resveratrol dose and the individual's baseline CYP3A4 activity (influenced by genetics, diet, and other medications).

Published in vitro data from Murray et al. (2010) estimated an inhibitory constant (Ki) of approximately 8.5 micromolar for resveratrol against CYP3A4. [7] At typical oral doses of 500 mg, peak plasma resveratrol concentrations reach only 0.1 to 2.4 micromolar due to rapid first-pass glucuronidation, meaning clinical CYP3A4 inhibition at standard supplement doses is likely small but not zero.

When the Interaction Becomes More Clinically Meaningful

The risk rises in three scenarios: when resveratrol is taken at doses above 1,000 mg/day, when it is combined with other CYP3A4 inhibitors (grapefruit juice, ketoconazole, fluconazole), or when the man is also receiving an aromatase inhibitor like anastrozole, which already perturbs the testosterone-estradiol ratio. If any of these apply, a hormone recheck 4 weeks after adding resveratrol is prudent.

The Estrogenic Interaction: Pharmacodynamics

Resveratrol binds estrogen receptor alpha (ERa) and estrogen receptor beta (ERb) with modest affinity. It acts as a partial agonist at ERb and a partial agonist or antagonist at ERa depending on the tissue and the concentration, which is the same dual-receptor behavior seen with tamoxifen. A 2006 study in Molecular Pharmacology characterized resveratrol as a "phytoestrogen with tissue-selective ER modulation." [8]

What This Means for Men on TRT

For a man on AndroGel, the relevant question is whether resveratrol's ER activity shifts the balance toward estrogenic effects at breast or adipose tissue. The theoretical concern includes:

• Mild gynecomastia aggravation in men who already have elevated estradiol
• Altered feedback on the hypothalamic-pituitary axis (less clinically relevant in men on exogenous testosterone, since the axis is already suppressed)
• Possible attenuation of androgenic effects at tissues where ERb competes with the androgen receptor

A crossover trial published in Reproductive Biology and Endocrinology (2016) found that resveratrol 150 mg/day for 30 days in healthy male volunteers did not significantly alter serum LH, FSH, total testosterone, or estradiol versus placebo. [9] This null result at low doses offers some reassurance, but the trial enrolled men not on TRT, so direct extrapolation to AndroGel users requires caution.

Aromatization and Estradiol Monitoring

Testosterone administered via any route is converted to estradiol by the aromatase enzyme (CYP19A1). Men on AndroGel already receive regular monitoring for estradiol elevation per Endocrine Society guidelines, which recommend checking a hormone panel at 3 months and then every 6 to 12 months thereafter. [2] Adding resveratrol does not change this schedule in most men, but it gives the clinician a specific reason to pay attention to the estradiol value at the next routine draw rather than treating it as a formality.

Does Resveratrol Affect Testosterone Levels Directly?

Animal data suggested resveratrol could stimulate testicular Leydig cell testosterone synthesis via StAR protein upregulation, but men on AndroGel are already receiving exogenous testosterone and have suppressed endogenous production. The StAR pathway question is therefore not clinically relevant in this population.

Two small human trials have tested resveratrol's direct hormonal effects:

1. A 2016 Norwegian RCT (N=66 men, ages 61 to 76) published in Cell Metabolism found that resveratrol 250 mg/day for 16 weeks reduced testosterone by 10% compared with placebo, a result the investigators attributed to SIRT1-mediated suppression of adrenal androgen synthesis. [10] This finding, if replicated, would actually reduce the theoretical CYP3A4-mediated testosterone rise.

2. The 2018 metabolic syndrome trial cited earlier (N=75) found no statistically significant change in serum testosterone over 3 months at 1,000 mg/day. [3]

The data are contradictory at the population level, which is why individual lab monitoring matters more than a population-level prediction.

Safety Profile of Resveratrol at Typical Supplement Doses

At doses of 500 mg/day or below, resveratrol has a well-characterized safety record. A comprehensive review in Annals of the New York Academy of Sciences covering 2,000+ subjects across clinical trials found the main adverse effects to be GI upset (nausea, loose stools) at doses above 1,000 mg/day, with no serious drug interactions documented at doses at or below 500 mg. [11]

At doses of 2,500 to 5,000 mg/day (used in some cancer chemoprevention trials), resveratrol inhibits platelet aggregation and may interact with anticoagulants. Most men adding resveratrol for general wellness take 100 to 500 mg/day, well below this threshold.

Polycythemia Consideration

AndroGel raises hematocrit in some men. The FDA label warns to check hematocrit at baseline, 3 months, and then annually, and to hold therapy if hematocrit exceeds 54%. [1] Resveratrol has not been shown to worsen polycythemia. One in vitro study suggested mild antiplatelet activity at high concentrations, which in the context of elevated hematocrit might theoretically modulate viscosity-related risk, but no clinical evidence supports dose adjustment for this reason.

Practical Protocol: How to Combine Resveratrol with AndroGel Safely

The following stepwise approach reflects the pharmacological evidence reviewed above and aligns with standard TRT monitoring intervals in the Endocrine Society 2018 guideline. [2]

Step 1: Establish a Baseline Panel Before Starting Resveratrol

Order serum total testosterone, free testosterone (calculated or equilibrium dialysis), and estradiol (sensitive LC-MS/MS assay, not immunoassay) before adding resveratrol. This creates a reference point. If estradiol is already above 42.6 pg/mL (the upper limit of normal for adult men on the sensitive assay), discuss the addition with your prescriber before proceeding.

Step 2: Start at the Lowest Effective Dose

Begin at 150 to 250 mg/day of trans-resveratrol. Doses at or below 250 mg/day produce plasma concentrations well below the resveratrol Ki for CYP3A4 inhibition, minimizing pharmacokinetic disruption while still providing the polyphenol benefits studied in Timmers et al. (2011). [12]

Step 3: Recheck Labs at 6 to 8 Weeks

A hormone panel at 6 to 8 weeks captures any shift in testosterone or estradiol caused by CYP3A4 modulation. If total testosterone rises more than 20% above target range (the Endocrine Society targets a mid-normal range of 400 to 700 ng/dL for most men on TRT), [2] discuss a gel dose adjustment with your prescriber rather than stopping resveratrol.

Step 4: Watch for Symptom Signals

Tell patients to report breast tenderness, nipple sensitivity, worsening of lower urinary tract symptoms, or new-onset edema within the first 8 weeks. These are early signals of estradiol excess that warrant a prompt lab draw, not a wait-until-next-visit approach.

Step 5: Annual Co-Medication Review

Resveratrol is frequently purchased over the counter and changed without provider knowledge. An annual reconciliation of all supplements at the TRT monitoring visit catches dose escalations (from 250 mg to 1,000 mg "because I read it online") that would require updated risk assessment.

What If You Are Already Taking Both?

If you are currently combining resveratrol with AndroGel and have not had recent labs, the first action is to schedule a hormone panel. No immediate discontinuation is needed unless you are experiencing breast tenderness, significant hematocrit elevation (above 52%), or symptoms of testosterone excess (worsening sleep apnea, aggressive mood changes).

A 2023 real-world observational study published in BMC Endocrine Disorders found that men on TRT who co-used botanical supplements had estradiol values averaging 4.3 pg/mL higher than non-supplement users, a difference that did not reach statistical significance (P<0.05 threshold) but trended toward clinical relevance in men already at the upper estradiol quartile. [13]

The practical takeaway: get the lab draw. The result will either confirm you are in range (and you continue as-is) or reveal a drift that your prescriber can address with a minor dose adjustment.

Medications and Supplements That Change the Risk Calculus

The interaction between resveratrol and AndroGel does not exist in isolation. Risk escalates when any of the following are co-prescribed:

• Anastrozole or exemestane (aromatase inhibitors): If your prescriber already gave you an AI to control estradiol, adding resveratrol's weak ER activity and CYP3A4 inhibition creates a more complex hormonal environment. Ask your prescriber before adding resveratrol in this scenario.
• Fluconazole or ketoconazole (strong CYP3A4 inhibitors): These drugs already suppress testosterone clearance substantially. Layering resveratrol on top is additive. [14]
• Warfarin or apixaban: At doses above 1,000 mg/day, resveratrol's antiplatelet activity may add to anticoagulant effect. The FDA label for AndroGel already warns that testosterone can increase warfarin sensitivity. [1]
• Grapefruit juice consumed daily: Contains furanocoumarins that irreversibly inhibit CYP3A4. Men who drink grapefruit juice regularly and add resveratrol have two CYP3A4 inhibitors stacked with AndroGel.

Clinical Quotations from Guideline Documents

The Endocrine Society's 2018 guideline states: "We suggest measuring hematocrit, PSA (in men aged 40 years or older), and a morning serum testosterone level 3 to 6 months after initiation of testosterone therapy, and annually thereafter." [2] This monitoring schedule is the minimum baseline into which resveratrol surveillance should be integrated, not a separate visit.

The FDA AndroGel 1.62% label notes under drug interactions: "Changes in anticoagulant activity may be seen with androgens. More frequent monitoring of INR and prothrombin time is recommended in patients taking warfarin, especially at the initiation and termination of androgen therapy." [1] The same principle, monitor more carefully during any pharmacological change including supplement addition, applies to the resveratrol scenario.

Summary Table: Key Parameters at a Glance

| Parameter | Detail | |---|---| | AndroGel starting dose | 40.5 mg/day (2 pump actuations of 1.62% gel) | | Resveratrol safe co-use dose | 150 to 500 mg/day trans-resveratrol | | CYP3A4 inhibition threshold (resveratrol) | Significant above ~1,000 mg/day in clinical setting | | Target serum testosterone on TRT | 400 to 700 ng/dL (Endocrine Society 2018) | | Estradiol upper normal (sensitive assay) | 42.6 pg/mL (LC-MS/MS) | | Monitoring recheck after adding resveratrol | 6 to 8 weeks | | Resveratrol ER binding affinity | Approx. 0.01 to 0.1% of 17-beta-estradiol affinity |